Literature DB >> 29116490

Impact of Sarcopenic Obesity on Failure to Rescue from Major Complications Following Pancreaticoduodenectomy for Cancer: Results from a Multicenter Study.

Nicolò Pecorelli1, Giovanni Capretti2, Marta Sandini3, Anna Damascelli4, Giulia Cristel4, Francesco De Cobelli4, Luca Gianotti3, Alessandro Zerbi2, Marco Braga5.   

Abstract

BACKGROUND: Failure to rescue (FTR) is a quality-of-care indicator in pancreatic surgery, but may also identify patients who may not tolerate major postoperative complications despite being treated with best available care. Previous studies found that high visceral adipose tissue-to-skeletal muscle ratio is associated with poor outcomes following pancreaticoduodenectomy (PD). The aim of the study is to assess the impact of sarcopenic obesity on occurrence of FTR from major complications in cancer patients undergoing PD.
METHODS: Prospectively collected data from three high-volume hospitals were reviewed. Total abdominal muscle area (TAMA) and visceral fat area (VFA) were assessed at preoperative staging computed tomography scan. Sarcopenic obesity was defined as high VFA/TAMA ratio. FTR was defined as postoperative mortality following major complication.
RESULTS: 120 patients with major complications were included. FTR occurred in 23 (19.2%) patients. The "seminal" complications leading to FTR were pancreatic or biliary fistula-related sepsis (n = 14), postoperative pancreatic fistula (POPF)-related hemorrhage (n = 5), and duodenojejunal anastomosis leak-related sepsis (n = 1). On univariate analysis, older age [odds ratio (OR) 3.5, p = 0.034], American Society of Anesthesiologists (ASA) score 3+ (OR 4.2, p = 0.005), cardiovascular disease (OR 3.3, p = 0.013), low serum albumin (OR 2.6, p = 0.042), sarcopenic obesity (OR 4.2, p = 0.009), POPF (OR 3.1, p = 0.027), and cardiorespiratory complications (OR 3.7, p = 0.011) were significantly associated with FTR. On multivariate analysis, sarcopenic obesity [OR 5.7, 95% confidence interval (CI) 1.6-20.7, p = 0.008], ASA score 3+ (OR 4.1, 95% CI 1.2-14.3, p = 0.025), and pancreatic fistula (OR 3.2, 95% CI 1.0-10.2, p = 0.045) were independently associated with FTR.
CONCLUSION: Sarcopenic obesity, low preoperative physical status, and occurrence of pancreatic fistula are associated with significantly higher risk of FTR from major complications after PD.

Entities:  

Mesh:

Year:  2017        PMID: 29116490     DOI: 10.1245/s10434-017-6216-5

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  12 in total

1.  Psoas muscle size as a magnetic resonance imaging biomarker of progression of pancreatitis.

Authors:  Andre E Modesto; Charlotte E Stuart; Jaelim Cho; Juyeon Ko; Ruma G Singh; Maxim S Petrov
Journal:  Eur Radiol       Date:  2020-02-10       Impact factor: 5.315

2.  Skeletal muscle index is an independent predictor of early recurrence in non-obese colon cancer patients.

Authors:  Dagmar Schaffler-Schaden; Christof Mittermair; Theresa Birsak; Michael Weiss; Tobias Hell; Gottfried Schaffler; Helmut Weiss
Journal:  Langenbecks Arch Surg       Date:  2020-06-05       Impact factor: 3.445

3.  Validation of original and alternative fistula risk scores in postoperative pancreatic fistula.

Authors:  Youngju Ryu; Sang Hyun Shin; Dae Joon Park; Naru Kim; Jin Seok Heo; Dong Wook Choi; In Woong Han
Journal:  J Hepatobiliary Pancreat Sci       Date:  2019-07-01       Impact factor: 7.027

4.  Power of computed-tomography-defined sarcopenia for prediction of morbidity after pancreaticoduodenectomy.

Authors:  Nicolas Linder; Alexander Schaudinn; Katharina Langenhan; Felix Krenzien; Hans-Michael Hau; Christian Benzing; Georgi Atanasov; Moritz Schmelzle; Thomas Kahn; Harald Busse; Michael Bartels; Ulf Neumann; Georg Wiltberger
Journal:  BMC Med Imaging       Date:  2019-04-27       Impact factor: 1.930

5.  Preoperative CT anthropometric measurements and pancreatic pathology increase risk for postoperative pancreatic fistula in patients following pancreaticoduodenectomy.

Authors:  Yun Hwa Roh; Bo Kyeong Kang; Soon-Young Song; Chul-Min Lee; Yun Kyung Jung; Mimi Kim
Journal:  PLoS One       Date:  2020-12-03       Impact factor: 3.240

6.  Evaluation of Muscle Mass and Stiffness with Limb Ultrasound in COVID-19 Survivors.

Authors:  Sarah Damanti; Marta Cilla; Bruno Tuscano; Rebecca De Lorenzo; Giuseppina Manganaro; Aurora Merolla; Giacomo Pacioni; Chiara Pomaranzi; Valeria Tiraferri; Sabina Martinenghi; Giordano Vitali; Emanuele Bosi; Caterina Conte; Andrea Giustina; Moreno Tresoldi; Patrizia Rovere Querini
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-17       Impact factor: 5.555

7.  Skeletal muscle wasting and long-term prognosis in patients undergoing rectal cancer surgery without neoadjuvant therapy.

Authors:  Alessandro Giani; Simone Famularo; Alessandro Fogliati; Luca Riva; Nicolò Tamini; Davide Ippolito; Luca Nespoli; Marco Braga; Luca Gianotti
Journal:  World J Surg Oncol       Date:  2022-02-25       Impact factor: 2.754

8.  Adverse Effects of Sarcopenic Obesity on Postoperative Complications after Major Hepatectomy in Patients with Hilar Cholangiocarcinoma.

Authors:  Okjoo Lee; Yong Chan Shin; Youngju Ryu; Sang Hyun Shin; Jin Seok Heo; Chang-Sup Lim; In Woong Han
Journal:  J Clin Med       Date:  2022-03-27       Impact factor: 4.241

9.  Impact of intramuscular adipose tissue content on short- and long-term outcomes of hepatectomy for colorectal liver metastasis: a retrospective analysis.

Authors:  Nobutoshi Horii; Yu Sawda; Takafumi Kumamoto; Nobuhiro Tsuchiya; Takashi Murakami; Yasuhiro Yabushita; Yuki Honma; Ryusei Matsuyama; Daisuke Morioka; Hirotoshi Akiyama; Itaru Endo
Journal:  World J Surg Oncol       Date:  2020-04-07       Impact factor: 2.754

10.  Risk prediction platform for pancreatic fistula after pancreatoduodenectomy using artificial intelligence.

Authors:  In Woong Han; Kyeongwon Cho; Youngju Ryu; Sang Hyun Shin; Jin Seok Heo; Dong Wook Choi; Myung Jin Chung; Oh Chul Kwon; Baek Hwan Cho
Journal:  World J Gastroenterol       Date:  2020-08-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.